Alterome Therapeutics Stock

alterome.comHealthcare / BioTech & PharmaFounded: 2021Funding to Date: $231.07MM

Alterome Therapeutics is a biopharmaceutical company with a mission to develop targeted cancer therapies, focusing on hard-to-treat cancer targets. The company utilizes a combination of advanced scientific disciplines, including chemistry, biology, pharmacology, and genomics aiming to create selective, small-molecule therapies aimed at transforming the lives of its patients. Alterome Therapeutics was founded by Eric A Murphy in 2021 and is headquartered in San Diego, CA.

Register To Buy and Sell Private Company Shares

For more details on private stock price information, financing and valuation for Alterome Therapeutics, register or login.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Alterome Therapeutics Stock Price

Forge Price 1
Price not yet available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Alterome Therapeutics Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
04/03/2024 Series B $132MM $xx.xx $356.19MM Blue Owl Capital, Boxer Capital, Canaan Partners, Colt Ventures, Digitalis Ventures, Driehaus Capital Management, Goldman Sachs Alternatives, Invus, Nextech Invest, Orbimed, Vida Ventures
Price per Share
$xx.xx
Shares Outstanding
32,314,919
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Blue Owl Capital, Boxer Capital, Canaan Partners, Colt Ventures, Digitalis Ventures, Driehaus Capital Management, Goldman Sachs Alternatives, Invus, Nextech Invest, Orbimed, Vida Ventures
11/02/2022 Series A-2 $35.27MM $xx.xx $186.39MM Boxer Capital, Colt Ventures, Nextech Invest, Orbimed, Vida Ventures
Price per Share
$xx.xx
Shares Outstanding
9,930,989
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Boxer Capital, Colt Ventures, Nextech Invest, Orbimed, Vida Ventures
01/19/2022 Series A $63.8MM $xx.xx $127.6MM Boxer Capital, Nextech Invest, Orbimed, Vida Ventures
Price per Share
$xx.xx
Shares Outstanding
21,554,051
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Boxer Capital, Nextech Invest, Orbimed, Vida Ventures

Alterome Therapeutics Investors Also Invested in These Private Companies

Goldman Sachs Alternatives

Leadership & Board

Leadership

Ryan Corcoran Ph.D
Co-Founder
Eric Murphy Ph.D
Co-Founder

Alterome Therapeutics stock FAQs

plusminus

Can you buy Alterome Therapeutics stock?

As Alterome Therapeutics is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Alterome Therapeutics, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
plusminus

How to buy Alterome Therapeutics stock?

To invest in a private company like Alterome Therapeutics through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell Alterome Therapeutics stock?

Yes, you may sell the Alterome Therapeutics stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
plusminus

How to sell Alterome Therapeutics stock?

If you hold private company shares of Alterome Therapeutics – whether as an employee or an early investor – Forge can help you sell them.

  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Alterome Therapeutics on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
plusminus

Is Alterome Therapeutics a public company?

No, Alterome Therapeutics is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is Alterome Therapeutics’ stock price?

Alterome Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Alterome Therapeutics private market stock price with Forge Data.
plusminus

What is Alterome Therapeutics’ stock ticker symbol?

Alterome Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Alterome Therapeutics News and Media Highlights

Alterome Therapeutics Raises $132M in Series B Financing

In a series B funding round led by Goldman Sachs Alternatives, Alterome raised $132 million.
Browse Insights
Updated on: Dec 17, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.